Carregant...
Synergistic Anti-Myeloma Activity of the Proteasome Inhibitor Marizomib and the IMiD(®) Immunomodulatory Drug Pomalidomide
The proteasome inhibitor bortezomib is an effective therapy for the treatment of relapsed and refractory multiple myeloma (RRMM); however, prolonged treatment can be associated with toxicity, peripheral neuropathy and drug resistance. Our earlier studies showed that the novel proteasome inhibitor ma...
Guardat en:
| Publicat a: | Br J Haematol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4715649/ https://ncbi.nlm.nih.gov/pubmed/26456076 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13780 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|